MoneyWorks4Me

Glenmark Pharma shines on getting USFDA’s nod for Fluticasone Propionate Nasal Spray

20 Aug 2026 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 2278.95, up by 23.95 points or 1.06% from its previous closing of Rs. 2255.00 on the BSE.

The scrip opened at Rs. 2255.95 and has touched a high and low of Rs. 2287.65 and Rs. 2255.00 respectively. So far 4547 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2471.05 on 29-Apr-2026 and a 52 week low of Rs. 1794.00 on 28-Oct-2025.

Last one week high and low of the scrip stood at Rs. 2341.00 and Rs. 2224.00 respectively. The current market cap of the company is Rs. 63952.11 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.53% and 13.81% respectively.

Glenmark Pharmaceuticals has received USFDA’s approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. The company’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC (NDA 020121) and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. 

According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of around $295.2 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries.

Glenmark Pharma. Share Price

2306.00 -19.00 (-0.82%)
21-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1900.90
Dr. Reddys Labs. 1175.00
Cipla 1426.20
Lupin 2193.00
Zydus Lifesciences 1120.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: